IL130524A - Stable liquid interferon formulations, a kit containing the same and a process for stabilizing the same - Google Patents

Stable liquid interferon formulations, a kit containing the same and a process for stabilizing the same

Info

Publication number
IL130524A
IL130524A IL13052497A IL13052497A IL130524A IL 130524 A IL130524 A IL 130524A IL 13052497 A IL13052497 A IL 13052497A IL 13052497 A IL13052497 A IL 13052497A IL 130524 A IL130524 A IL 130524A
Authority
IL
Israel
Prior art keywords
same
liquid
interferon
stabilizing
stable liquid
Prior art date
Application number
IL13052497A
Other languages
English (en)
Other versions
IL130524A0 (en
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21875893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL130524(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of IL130524A0 publication Critical patent/IL130524A0/xx
Publication of IL130524A publication Critical patent/IL130524A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL13052497A 1996-12-24 1997-12-23 Stable liquid interferon formulations, a kit containing the same and a process for stabilizing the same IL130524A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3435396P 1996-12-24 1996-12-24
PCT/US1997/023817 WO1998028007A1 (en) 1996-12-24 1997-12-23 Stable liquid interferon formulations

Publications (2)

Publication Number Publication Date
IL130524A0 IL130524A0 (en) 2000-06-01
IL130524A true IL130524A (en) 2005-08-31

Family

ID=21875893

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13052497A IL130524A (en) 1996-12-24 1997-12-23 Stable liquid interferon formulations, a kit containing the same and a process for stabilizing the same

Country Status (28)

Country Link
EP (1) EP0948358B2 (da)
JP (5) JP4878664B2 (da)
KR (2) KR20000069664A (da)
CN (2) CN1733296B (da)
AT (1) ATE270899T1 (da)
AU (1) AU738362B2 (da)
BG (2) BG65418B1 (da)
BR (1) BR9714434A (da)
CA (1) CA2275890C (da)
CZ (1) CZ300636B6 (da)
DE (1) DE69729880T3 (da)
DK (1) DK0948358T4 (da)
EA (1) EA002754B1 (da)
EE (2) EE04266B1 (da)
ES (1) ES2224290T5 (da)
HK (2) HK1025040A1 (da)
HU (1) HU224222B1 (da)
IL (1) IL130524A (da)
IS (1) IS2070B (da)
MX (1) MX337876B (da)
NO (1) NO327844B1 (da)
NZ (2) NZ336548A (da)
PL (1) PL193447B1 (da)
PT (1) PT948358E (da)
SI (1) SI0948358T2 (da)
SK (1) SK284989B6 (da)
TR (1) TR199901968T2 (da)
WO (1) WO1998028007A1 (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000069664A (ko) * 1996-12-24 2000-11-25 아스트루 마이클 제이 안정한 액체 인터페론 제제
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
DK1017413T4 (da) 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
CA2375779A1 (en) * 1999-05-31 2000-12-07 Mitsubishi Chemical Corporation Lyophilized hgf preparation
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
JP4340540B2 (ja) * 2002-01-18 2009-10-07 旭化成ファーマ株式会社 可溶性トロンボモジュリン高濃度含有製剤
CA2490342C (en) 2002-06-21 2015-06-16 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
CA2525224A1 (en) 2003-05-23 2004-12-02 Michael Bech Jensen Protein stabilization in solution
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
BRPI0413518A (pt) 2003-08-14 2006-10-10 Novo Nordisk Healthcare Ag composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
KR20070010115A (ko) * 2003-11-13 2007-01-22 알자 코포레이션 경피전달용 조성물 및 장치
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
DK2298287T3 (da) 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Stabiliserede sammensætninger af faktor VII-polypeptider
MXPA06014079A (es) * 2004-06-01 2007-02-15 Ares Trading Sa Metodo para estabilizar proteinas.
US20080193997A1 (en) * 2004-08-24 2008-08-14 Kenji Kangawa Liquid Preparation of Physiologically Active Peptide
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CN101056890B (zh) 2004-11-10 2012-05-09 诺华疫苗和诊断公司 脱酰胺基干扰素-β
CN101102739B (zh) * 2005-01-12 2017-02-08 比奥根Ma公司 运输干扰素‑β的方法
US20060188555A1 (en) * 2005-01-21 2006-08-24 Micheal Cormier Therapeutic peptide formulations with improved stability
EP1899462B1 (en) 2005-07-02 2011-03-09 Arecor Limited Stable aqueous systems comprising proteins
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA2810522A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
PL2868315T3 (pl) * 2007-12-04 2018-06-29 Biogen Chesapeake Llc Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty
CN101878043A (zh) 2007-12-20 2010-11-03 默克雪兰诺有限公司 PEG-干扰素-β制剂
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
JP2011519848A (ja) 2008-05-01 2011-07-14 アレコー リミテッド タンパク質製剤
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
DE102008051574A1 (de) 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2531218B1 (en) 2010-02-04 2018-12-12 CSL Behring AG Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
DE102010011430A1 (de) * 2010-03-15 2011-09-15 Kurt Koch Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
JP5538568B2 (ja) * 2010-12-09 2014-07-02 丸石製薬株式会社 アセトアミノフェンの安定化剤
SI2686002T1 (en) * 2011-03-15 2018-06-29 Biogen Ma Inc. A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CA2864740A1 (en) * 2012-04-19 2013-10-24 C.R. Bard, Inc. Infusates with enhanced ph stability under ethylene oxide sterilization
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ITMI20120913A1 (it) 2012-05-28 2013-11-29 Nicoletta Maxia Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
CN103143000B (zh) * 2013-03-07 2014-11-05 安徽安科生物工程（集团）股份有限公司 一种重组人干扰素α2b制剂
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
JP2014208669A (ja) * 2014-06-17 2014-11-06 株式会社スリー・ディー・マトリックス タンパク質の凝集抑制剤
MX2018015089A (es) 2016-06-10 2019-05-13 Boehringer Ingelheim Int Combinacion de linagliptina y metformina.
KR101943160B1 (ko) 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
AU2018321335A1 (en) 2017-08-22 2020-02-27 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
KR20210009982A (ko) * 2019-07-18 2021-01-27 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
CN110714051B (zh) * 2019-11-20 2023-04-07 迈克生物股份有限公司 蛋白c活性测定试剂盒
MX2022013662A (es) * 2020-04-29 2023-02-01 Abion Inc Variante del interferon-beta humano con doble mutacion y metodo para mejorar la estabilidad de la variante del interferon-beta humano.
CN114177273B (zh) * 2021-11-29 2024-05-28 苏州人本药业有限公司 一种含有神经毒素的液体制剂及其制备方法
WO2023129502A1 (en) * 2021-12-27 2023-07-06 Enalare Therapeutics Inc. Respiratory stimulant parenteral formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57175125A (en) * 1981-04-20 1982-10-28 Wakunaga Yakuhin Kk Preparation of beta-interferon
DE3262575D1 (en) * 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
JPS63196268A (ja) * 1987-02-10 1988-08-15 Kanegafuchi Chem Ind Co Ltd 無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
JPH02124832A (ja) * 1988-07-08 1990-05-14 Toray Ind Inc インターヘェロンβ組成物
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon
TW249202B (da) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
CA2185353A1 (en) * 1994-04-08 1995-10-19 David A. Hafler Treatment of autoimmune disease using oral tolerization and/or type i interferon
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
KR20000069664A (ko) * 1996-12-24 2000-11-25 아스트루 마이클 제이 안정한 액체 인터페론 제제

Also Published As

Publication number Publication date
CA2275890C (en) 2011-11-01
EP0948358B2 (en) 2011-11-23
KR20000069664A (ko) 2000-11-25
DE69729880T2 (de) 2005-07-07
DK0948358T3 (da) 2004-11-08
SK284989B6 (sk) 2006-04-06
WO1998028007A1 (en) 1998-07-02
AU738362B2 (en) 2001-09-13
BR9714434A (pt) 2000-05-02
NO993121D0 (no) 1999-06-23
NO993121L (no) 1999-08-24
JP2001519770A (ja) 2001-10-23
HK1025040A1 (en) 2000-11-03
CN1245434A (zh) 2000-02-23
PL334365A1 (en) 2000-02-28
NO327844B1 (no) 2009-10-05
JP5851695B2 (ja) 2016-02-03
CN1222315C (zh) 2005-10-12
ATE270899T1 (de) 2004-07-15
ES2224290T5 (es) 2012-03-12
TR199901968T2 (xx) 1999-12-21
IS5087A (is) 1999-06-21
EP0948358B1 (en) 2004-07-14
SI0948358T1 (en) 2005-04-30
BG65171B1 (bg) 2007-05-31
NZ512792A (en) 2002-11-26
CA2275890A1 (en) 1998-07-02
JP4878664B2 (ja) 2012-02-15
EA002754B1 (ru) 2002-08-29
JP2007204501A (ja) 2007-08-16
CZ228299A3 (cs) 1999-12-15
JP2014098029A (ja) 2014-05-29
DE69729880T3 (de) 2012-05-10
EP0948358A1 (en) 1999-10-13
HUP0000829A2 (en) 2000-07-28
HUP0000829A3 (en) 2002-01-28
DE69729880D1 (de) 2004-08-19
BG109523A (en) 2007-05-31
EE04266B1 (et) 2004-04-15
PL193447B1 (pl) 2007-02-28
PT948358E (pt) 2004-10-29
DK0948358T4 (da) 2012-03-19
EE200300127A (et) 2003-06-16
EA199900597A1 (ru) 2000-02-28
MX337876B (es) 2016-03-22
BG65418B1 (bg) 2008-07-31
ES2224290T3 (es) 2005-03-01
SI0948358T2 (sl) 2012-03-30
AU5619198A (en) 1998-07-17
JP2011068694A (ja) 2011-04-07
KR101042660B1 (ko) 2011-06-20
HK1092048A1 (en) 2007-02-02
EE04223B1 (et) 2004-02-16
IL130524A0 (en) 2000-06-01
CN1733296B (zh) 2010-05-26
IS2070B (is) 2005-12-15
NZ336548A (en) 2001-09-28
SK85899A3 (en) 2000-01-18
KR20070052363A (ko) 2007-05-21
BG103594A (en) 2000-04-28
HU224222B1 (hu) 2005-06-28
JP2012006979A (ja) 2012-01-12
CZ300636B6 (cs) 2009-07-08
CN1733296A (zh) 2006-02-15
EE9900313A (et) 2000-04-17

Similar Documents

Publication Publication Date Title
IL130524A (en) Stable liquid interferon formulations, a kit containing the same and a process for stabilizing the same
CA2113995A1 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
AU6340686A (en) Pharmaceutical and dietary composition
CA2032499A1 (en) Polypeptide derivatives
PL319833A1 (en) Compounds and composition for carrying active media
EP2145897A3 (en) Therapeutic methods and compositions based on serrate proteins and nucleic acids
GR3024632T3 (en) Sustained-release protein formulations.
EP1077070A3 (en) Oral drug delivery compositions
AU4009789A (en) Recombinant natural killer cell activator
LTIP610A (en) Inhibitors of cells proliferation, pharmaceutical composition and method for preparation of compounds
EP0612530A3 (en) Pharmaceutical preparations which contain the cytotoxic tumor factor.
AU3494093A (en) S-lipophilic aliphatic carbonyl {n-mercaptoacyl-(amino acid or peptide)} compounds as antihypertensive agents
EP0063328A3 (en) Compositions containing secretin and method for preventing the adsorption of secretin
JPS57128662A (en) Amino acid mixture composition
Sebald et al. Cooperation of mitochondrial and cytoplasmic protein synthesis in the formation of cytochrome c oxidase
ES8204713A1 (es) Un procedimiento para aislar un polipeptido purificado
ZA837267B (en) Substituted n-carboxymethyl-(amino acid)-pyrrolidine-alkanoic acids useful as antihypertensive agents
MX9709907A (es) Formulaciones de suspension de peptido/proteina.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired